The Immunostimulatory RNA RN7SL1 Enables CAR-T Cells to Enhance Autonomous and Endogenous Immune Function

Overview

Journal Cell

Publisher Cell Press

Specialty Cell Biology

Date 2021 Aug 31

PMID 34464586

Citations 76

Authors

Lexus R Johnson

Daniel Y Lee

Jacqueline S Eacret

Darwin Ye

Carl H June

Andy J Minn

Affiliations

Soon will be listed here.

Abstract

Poor tumor infiltration, development of exhaustion, and antigen insufficiency are common mechanisms that limit chimeric antigen receptor (CAR)-T cell efficacy. Delivery of pattern recognition receptor agonists is one strategy to improve immune function; however, targeting these agonists to immune cells is challenging, and off-target signaling in cancer cells can be detrimental. Here, we engineer CAR-T cells to deliver RN7SL1, an endogenous RNA that activates RIG-I/MDA5 signaling. RN7SL1 promotes expansion and effector-memory differentiation of CAR-T cells. Moreover, RN7SL1 is deployed in extracellular vesicles and selectively transferred to immune cells. Unlike other RNA agonists, transferred RN7SL1 restricts myeloid-derived suppressor cell (MDSC) development, decreases TGFB in myeloid cells, and fosters dendritic cell (DC) subsets with costimulatory features. Consequently, endogenous effector-memory and tumor-specific T cells also expand, allowing rejection of solid tumors with CAR antigen loss. Supported by improved endogenous immunity, CAR-T cells can now co-deploy peptide antigens with RN7SL1 to enhance efficacy, even when heterogenous CAR antigen tumors lack adequate neoantigens.

Citing Articles

Strategies to Overcome Antigen Heterogeneity in CAR-T Cell Therapy.

Zhang B, Wu J, Jiang H, Zhou M Cells. 2025; 14(5).

PMID: 40072049 PMC: 11899321. DOI: 10.3390/cells14050320.

Enhancing CAR T-Cell Function with Domains of Innate Immunity Sensors.

Mlakar T, Skrbinek M, Fink T, Lainscek D Int J Mol Sci. 2025; 26(3).

PMID: 39941106 PMC: 11818292. DOI: 10.3390/ijms26031339.

Engineered Cellular Therapies for the Treatment of Thoracic Cancers.

Erickson S, Manning B, Kumar A, Patel M Cancers (Basel). 2025; 17(1.

PMID: 39796666 PMC: 11718842. DOI: 10.3390/cancers17010035.

The bidirectional interplay between T cell-based immunotherapies and the tumor microenvironment.

Pherez-Farah A, Boncompagni G, Chudnovskiy A, Pasqual G Cancer Immunol Res. 2025; .

PMID: 39786986 PMC: 7617322. DOI: 10.1158/2326-6066.CIR-24-0857.

Myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment and their targeting in cancer therapy.

He S, Zheng L, Qi C Mol Cancer. 2025; 24(1):5.

PMID: 39780248 PMC: 11707952. DOI: 10.1186/s12943-024-02208-3.

References

Hammerich L, Marron T, Upadhyay R, Svensson-Arvelund J, Dhainaut M, Hussein S . Systemic clinical tumor regressions and potentiation of PD1 blockade with in situ vaccination. Nat Med. 2019; 25(5):814-824. DOI: 10.1038/s41591-019-0410-x. View

Alshetaiwi H, Pervolarakis N, McIntyre L, Ma D, Nguyen Q, Rath J . Defining the emergence of myeloid-derived suppressor cells in breast cancer using single-cell transcriptomics. Sci Immunol. 2020; 5(44). PMC: 7219211. DOI: 10.1126/sciimmunol.aay6017. View

Reuter J, Mathews D . RNAstructure: software for RNA secondary structure prediction and analysis. BMC Bioinformatics. 2010; 11:129. PMC: 2984261. DOI: 10.1186/1471-2105-11-129. View

Keskin D, Anandappa A, Sun J, Tirosh I, Mathewson N, Li S . Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature. 2018; 565(7738):234-239. PMC: 6546179. DOI: 10.1038/s41586-018-0792-9. View

Hudson W, Gensheimer J, Hashimoto M, Wieland A, Valanparambil R, Li P . Proliferating Transitory T Cells with an Effector-like Transcriptional Signature Emerge from PD-1 Stem-like CD8 T Cells during Chronic Infection. Immunity. 2019; 51(6):1043-1058.e4. PMC: 6920571. DOI: 10.1016/j.immuni.2019.11.002. View

Ramanjulu J, Pesiridis G, Yang J, Concha N, Singhaus R, Zhang S . Design of amidobenzimidazole STING receptor agonists with systemic activity. Nature. 2018; 564(7736):439-443. DOI: 10.1038/s41586-018-0705-y. View

Nabet B, Qiu Y, Shabason J, Wu T, Yoon T, Kim B . Exosome RNA Unshielding Couples Stromal Activation to Pattern Recognition Receptor Signaling in Cancer. Cell. 2017; 170(2):352-366.e13. PMC: 6611169. DOI: 10.1016/j.cell.2017.06.031. View

Tang N, Cheng C, Zhang X, Qiao M, Li N, Mu W . TGF-β inhibition via CRISPR promotes the long-term efficacy of CAR T cells against solid tumors. JCI Insight. 2020; 5(4). PMC: 7101140. DOI: 10.1172/jci.insight.133977. View

Majzner R, Rietberg S, Sotillo E, Dong R, Vachharajani V, Labanieh L . Tuning the Antigen Density Requirement for CAR T-cell Activity. Cancer Discov. 2020; 10(5):702-723. PMC: 7939454. DOI: 10.1158/2159-8290.CD-19-0945. View

10.

Wu T, Madireddi S, de Almeida P, Banchereau R, Chen Y, Chitre A . Peripheral T cell expansion predicts tumour infiltration and clinical response. Nature. 2020; 579(7798):274-278. DOI: 10.1038/s41586-020-2056-8. View

11.

Choudhuri K, Llodra J, Roth E, Tsai J, Gordo S, Wucherpfennig K . Polarized release of T-cell-receptor-enriched microvesicles at the immunological synapse. Nature. 2014; 507(7490):118-23. PMC: 3949170. DOI: 10.1038/nature12951. View

12.

Stone A, Green R, Wilkins C, Hemann E, Gale Jr M . RIG-I-like receptors direct inflammatory macrophage polarization against West Nile virus infection. Nat Commun. 2019; 10(1):3649. PMC: 6692387. DOI: 10.1038/s41467-019-11250-5. View

13.

Sotillo E, Barrett D, Black K, Bagashev A, Oldridge D, Wu G . Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy. Cancer Discov. 2015; 5(12):1282-95. PMC: 4670800. DOI: 10.1158/2159-8290.CD-15-1020. View

14.

Halic M, Beckmann R . The signal recognition particle and its interactions during protein targeting. Curr Opin Struct Biol. 2005; 15(1):116-25. DOI: 10.1016/j.sbi.2005.01.013. View

15.

Klebanoff C, Wolchok J . Shared cancer neoantigens: Making private matters public. J Exp Med. 2017; 215(1):5-7. PMC: 5748868. DOI: 10.1084/jem.20172188. View

16.

Catalano M, ODriscoll L . Inhibiting extracellular vesicles formation and release: a review of EV inhibitors. J Extracell Vesicles. 2020; 9(1):1703244. PMC: 6968539. DOI: 10.1080/20013078.2019.1703244. View

17.

Roybal K, Williams J, Morsut L, Rupp L, Kolinko I, Choe J . Engineering T Cells with Customized Therapeutic Response Programs Using Synthetic Notch Receptors. Cell. 2016; 167(2):419-432.e16. PMC: 5072533. DOI: 10.1016/j.cell.2016.09.011. View

18.

Liu X, Ranganathan R, Jiang S, Fang C, Sun J, Kim S . A Chimeric Switch-Receptor Targeting PD1 Augments the Efficacy of Second-Generation CAR T Cells in Advanced Solid Tumors. Cancer Res. 2016; 76(6):1578-90. PMC: 4800826. DOI: 10.1158/0008-5472.CAN-15-2524. View

19.

Sivick K, Desbien A, Glickman L, Reiner G, Corrales L, Surh N . Magnitude of Therapeutic STING Activation Determines CD8 T Cell-Mediated Anti-tumor Immunity. Cell Rep. 2018; 25(11):3074-3085.e5. DOI: 10.1016/j.celrep.2018.11.047. View

20.

Qiu X, Mao Q, Tang Y, Wang L, Chawla R, Pliner H . Reversed graph embedding resolves complex single-cell trajectories. Nat Methods. 2017; 14(10):979-982. PMC: 5764547. DOI: 10.1038/nmeth.4402. View